Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luspatercept versus placebo in transfusion-dependent myelofibrosis-associated anemia on JAK2 inhibitor therapy
2020-000607-36Phase 3Active
- Sponsor
- Celgene Corporation
- Start
- Oct 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelophthisis comparing Luspatercept plus concomitant JAK2 inhibitor with Placebo plus concomitant JAK2 inhibitor (2 arms). Primary endpoint: Proportion of subjects who become red blood cell transfusion-free during any consecutive 12-week period. Started Oct 2020; status: active.
02
Drugs
luspatercept
03
Conditions
myelophthisis
Beyond the preview
Go deeper on 2020-000607-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000607-36.